Novo Nordisk A/S (NOVO-B.CO)
DKK 455.9
(2.62%)
DKK 455.9
(2.62%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 12.61 Billion DKK | -3.94% |
| 2022 | 13.13 Billion DKK | -17.54% |
| 2021 | 15.92 Billion DKK | 763.27% |
| 2020 | -2.4 Billion DKK | 78.16% |
| 2019 | -10.99 Billion DKK | 27.32% |
| 2018 | -15.12 Billion DKK | 11.86% |
| 2017 | -17.15 Billion DKK | 7.06% |
| 2016 | -18.46 Billion DKK | -16.47% |
| 2015 | -15.85 Billion DKK | -15.9% |
| 2014 | -13.67 Billion DKK | -30.09% |
| 2013 | -10.51 Billion DKK | 4.89% |
| 2012 | -11.05 Billion DKK | 11.96% |
| 2011 | -12.55 Billion DKK | -28.2% |
| 2010 | -9.79 Billion DKK | 1.16% |
| 2009 | -9.9 Billion DKK | -52.83% |
| 2008 | -6.48 Billion DKK | -87.26% |
| 2007 | -3.46 Billion DKK | -97.01% |
| 2006 | -1.75 Billion DKK | -190.38% |
| 2005 | -605.18 Million DKK | 65.43% |
| 2004 | -1.75 Billion DKK | -474.78% |
| 2003 | 467.1 Million DKK | 1419.93% |
| 2002 | -35.38 Million DKK | -205.9% |
| 2001 | 33.41 Million DKK | -93.17% |
| 2000 | 489.29 Million DKK | -83.16% |
| 1999 | 2.9 Billion DKK | 48.3% |
| 1998 | 1.95 Billion DKK | -1.06% |
| 1997 | 1.98 Billion DKK | 489.71% |
| 1996 | -508.11 Million DKK | 46.7% |
| 1995 | -953.22 Million DKK | 55.08% |
| 1994 | -2.12 Billion DKK | -51.32% |
| 1993 | -1.4 Billion DKK | 37.26% |
| 1992 | -2.23 Billion DKK | 24.6% |
| 1991 | -2.96 Billion DKK | -100.6% |
| 1990 | -1.47 Billion DKK | -446.82% |
| 1989 | 426.18 Million DKK | 201.64% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 20.6 Billion DKK | 63.34% |
| 2024 Q2 | 4.23 Billion DKK | -79.43% |
| 2023 Q4 | 12.61 Billion DKK | 449.71% |
| 2023 Q3 | -3.6 Billion DKK | -187.34% |
| 2023 Q2 | 4.13 Billion DKK | -60.97% |
| 2023 FY | 12.61 Billion DKK | -3.94% |
| 2023 Q1 | 10.58 Billion DKK | -19.41% |
| 2022 Q4 | 13.13 Billion DKK | 626.08% |
| 2022 Q3 | -2.49 Billion DKK | -193.27% |
| 2022 Q2 | 2.67 Billion DKK | -77.86% |
| 2022 FY | 13.13 Billion DKK | -17.54% |
| 2022 Q1 | 12.08 Billion DKK | -24.11% |
| 2021 FY | 15.92 Billion DKK | 763.27% |
| 2021 Q1 | 3.97 Billion DKK | 265.43% |
| 2021 Q2 | -10.46 Billion DKK | -363.47% |
| 2021 Q3 | -15.74 Billion DKK | -50.45% |
| 2021 Q4 | 15.92 Billion DKK | 201.14% |
| 2020 Q1 | -5.65 Billion DKK | 48.55% |
| 2020 FY | -2.4 Billion DKK | 78.16% |
| 2020 Q3 | -21.37 Billion DKK | -3.11% |
| 2020 Q2 | -20.73 Billion DKK | -266.6% |
| 2020 Q4 | -2.4 Billion DKK | 88.77% |
| 2019 Q3 | -14.41 Billion DKK | -40.97% |
| 2019 Q4 | -10.99 Billion DKK | 23.74% |
| 2019 FY | -10.99 Billion DKK | 27.32% |
| 2019 Q1 | -4.73 Billion DKK | 68.68% |
| 2019 Q2 | -10.22 Billion DKK | -115.85% |
| 2018 Q2 | -18.14 Billion DKK | -76.43% |
| 2018 FY | -15.12 Billion DKK | 11.86% |
| 2018 Q3 | -16.06 Billion DKK | 11.47% |
| 2018 Q1 | -10.28 Billion DKK | 40.06% |
| 2018 Q4 | -15.12 Billion DKK | 5.86% |
| 2017 Q1 | -16.15 Billion DKK | 12.52% |
| 2017 Q3 | -18.87 Billion DKK | 3.92% |
| 2017 FY | -17.15 Billion DKK | 7.06% |
| 2017 Q4 | -17.15 Billion DKK | 9.09% |
| 2017 Q2 | -19.64 Billion DKK | -21.63% |
| 2016 Q2 | -12.76 Billion DKK | -189.23% |
| 2016 Q4 | -18.46 Billion DKK | -31.11% |
| 2016 Q1 | -4.41 Billion DKK | 72.16% |
| 2016 Q3 | -14.08 Billion DKK | -10.34% |
| 2016 FY | -18.46 Billion DKK | -16.47% |
| 2015 FY | -15.85 Billion DKK | -15.9% |
| 2015 Q2 | -11.1 Billion DKK | -105.94% |
| 2015 Q1 | -5.39 Billion DKK | 60.59% |
| 2015 Q4 | -15.85 Billion DKK | -6.71% |
| 2015 Q3 | -14.85 Billion DKK | -33.82% |
| 2014 Q2 | -4.59 Billion DKK | -150.27% |
| 2014 FY | -13.67 Billion DKK | -30.09% |
| 2014 Q4 | -13.67 Billion DKK | -15.7% |
| 2014 Q3 | -11.82 Billion DKK | -157.24% |
| 2014 Q1 | -1.83 Billion DKK | 82.54% |
| 2013 FY | -10.51 Billion DKK | 4.89% |
| 2013 Q1 | -6.88 Billion DKK | 37.72% |
| 2013 Q4 | -10.51 Billion DKK | -20.04% |
| 2013 Q3 | -8.75 Billion DKK | -19.09% |
| 2013 Q2 | -7.35 Billion DKK | -6.83% |
| 2012 Q3 | -12.39 Billion DKK | -51.52% |
| 2012 Q4 | -11.05 Billion DKK | 10.8% |
| 2012 Q2 | -8.17 Billion DKK | -8.49% |
| 2012 FY | -11.05 Billion DKK | 11.96% |
| 2012 Q1 | -7.53 Billion DKK | 39.96% |
| 2011 Q4 | -12.55 Billion DKK | 1.29% |
| 2011 FY | -12.55 Billion DKK | -28.2% |
| 2011 Q1 | -8.78 Billion DKK | 10.29% |
| 2011 Q2 | -11.18 Billion DKK | -27.3% |
| 2011 Q3 | -12.71 Billion DKK | -13.74% |
| 2010 Q1 | -7.52 Billion DKK | 24.07% |
| 2010 Q2 | -7.1 Billion DKK | 5.56% |
| 2010 FY | -9.79 Billion DKK | 1.16% |
| 2010 Q3 | -10.35 Billion DKK | -45.76% |
| 2010 Q4 | -9.79 Billion DKK | 5.44% |
| 2009 FY | -9.9 Billion DKK | -52.83% |
| 2009 Q3 | -9.03 Billion DKK | -21.6% |
| 2009 Q1 | -5.58 Billion DKK | 13.81% |
| 2009 Q2 | -7.43 Billion DKK | -32.98% |
| 2009 Q4 | -9.9 Billion DKK | -9.65% |
| 2008 Q3 | -5.35 Billion DKK | -15.5% |
| 2008 Q4 | -6.48 Billion DKK | -20.98% |
| 2008 Q2 | -4.63 Billion DKK | -60.31% |
| 2008 Q1 | -2.89 Billion DKK | 16.4% |
| 2008 FY | -6.48 Billion DKK | -87.26% |
| 2007 Q2 | -2.56 Billion DKK | -44.29% |
| 2007 Q4 | -3.46 Billion DKK | -19.87% |
| 2007 FY | -3.46 Billion DKK | -97.01% |
| 2007 Q1 | -1.78 Billion DKK | -1.31% |
| 2007 Q3 | -2.88 Billion DKK | -12.44% |
| 2006 Q4 | -1.75 Billion DKK | 14.64% |
| 2006 Q3 | -2.05 Billion DKK | -16.01% |
| 2006 FY | -1.75 Billion DKK | -190.38% |
| 2006 Q2 | -1.77 Billion DKK | -152.87% |
| 2006 Q1 | -701.8 Million DKK | -15.97% |
| 2005 Q2 | -584.67 Million DKK | 9.97% |
| 2005 Q3 | -1.37 Billion DKK | -134.47% |
| 2005 Q4 | -605.18 Million DKK | 55.85% |
| 2005 FY | -605.18 Million DKK | 65.43% |
| 2005 Q1 | -649.44 Million DKK | 62.9% |
| 2004 Q1 | 66.46 Million DKK | -85.77% |
| 2004 Q2 | -804.34 Million DKK | -1310.23% |
| 2004 Q3 | -1.75 Billion DKK | -118.74% |
| 2004 Q4 | -1.75 Billion DKK | 0.5% |
| 2004 FY | -1.75 Billion DKK | -474.78% |
| 2003 FY | 467.1 Million DKK | 1419.93% |
| 2003 Q4 | 467.1 Million DKK | 0.0% |
| 2002 Q4 | -35.38 Million DKK | 0.0% |
| 2002 FY | -35.38 Million DKK | -205.9% |
| 2001 FY | 33.41 Million DKK | -93.17% |
| 2001 Q4 | 33.41 Million DKK | 0.0% |
| 2000 FY | 489.29 Million DKK | -83.16% |
| 2000 Q4 | 489.29 Million DKK | 0.0% |
| 1999 FY | 2.9 Billion DKK | 48.3% |
| 1999 Q4 | 2.9 Billion DKK | 0.0% |
| 1998 FY | 1.95 Billion DKK | -1.06% |
| 1998 Q4 | 1.95 Billion DKK | 0.0% |
| 1997 Q4 | 1.98 Billion DKK | 0.0% |
| 1997 FY | 1.98 Billion DKK | 489.71% |
| 1996 FY | -508.11 Million DKK | 46.7% |
| 1996 Q4 | -508.11 Million DKK | 0.0% |
| 1995 FY | -953.22 Million DKK | 55.08% |
| 1995 Q4 | -953.22 Million DKK | 0.0% |
| 1994 Q4 | -2.12 Billion DKK | 0.0% |
| 1994 FY | -2.12 Billion DKK | -51.32% |
| 1993 FY | -1.4 Billion DKK | 37.26% |
| 1993 Q4 | -1.4 Billion DKK | 0.0% |
| 1992 FY | -2.23 Billion DKK | 24.6% |
| 1992 Q4 | -2.23 Billion DKK | 0.0% |
| 1991 Q4 | -2.96 Billion DKK | 0.0% |
| 1991 FY | -2.96 Billion DKK | -100.6% |
| 1990 FY | -1.47 Billion DKK | -446.82% |
| 1990 Q4 | -1.47 Billion DKK | 0.0% |
| 1989 Q4 | 426.18 Million DKK | 0.0% |
| 1989 FY | 426.18 Million DKK | 201.64% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ALK-Abelló A/S | 291 Million DKK | -4234.708% |
| Bavarian Nordic A/S | -1.33 Billion DKK | 1047.045% |
| Genmab A/S | -14.09 Billion DKK | 189.48% |
| Gubra A/S | 18.03 Million DKK | -69830.147% |
| Orphazyme A/S | -11.26 Million DKK | 112035.398% |
| Pharma Equity Group A/S | 25.99 Million DKK | -48434.052% |
| Zealand Pharma A/S | -249.03 Million DKK | 5165.131% |